About R. Fletcher
R. Fletcher is a director at ClearPoint Neuro.
Form D filings name R. Fletcher as a director at Metabolon.
R. Fletcher reports to the SEC as a director of 9 public companies, including KORU Medical Systems (KRMD), OptiNose (OPTN) and Vyant Bio (VYNT).
R. Fletcher first appears on SEC filings in 2006.
Experience
This experience comes from SEC filings. The years are when the filings name R. Fletcher in the role, so the role may have started earlier or lasted longer.
CI
ClearPoint Neuro, Inc.
Director
2017 – 2026 · Public company (CLPT)
KI
KORU Medical Systems, Inc.
Director
2019 – 2026 · Public company (KRMD)
OI
OptiNose, Inc.
Director
2022 – 2025 · Public company (OPTN)
VI
Vyant Bio, Inc.
Director
2021 – 2023 · Public company (VYNT)
AI
Axcelis Technologies Inc.
Director
2006 – 2021 · Public company (ACLS)
SC
Spectranetics Corp.
Director
2007 – 2017 · Public company (SPNC)
AI
Adhera Therapeutics, Inc.
Director
2011 · Public company (ATRX)
AI
Autoimmune Inc.
Director
2006 – 2009 · Public company (AIMM)
PI
Panacos Pharmaceuticals, Inc.
Director
2006 – 2008 · Public company (PANC)
Key Colleagues at Startups
The people R. Fletcher works with at each company, as listed on that company's latest Form D.
Metabolon, Inc. · Form D, Jan 10, 2025
GI
Gerald Haines II
Executive officer
JO
John Oxaal
Director
JL
Jan Lundberg
Director
RB
R. Barry
Director
RC
Robert Cascella
Director
RH
Rohan Hastie
Chief Executive Officer and director
TS
Todd Schermerhorn
Director